Project UpdateMay 19, 2026, 07:02 AM
Korro Bio Adds KRRO-111 to Pipeline for AATD Treatment
AI Summary
Korro Bio, Inc. announced the addition of KRRO-111 to its pipeline as a development candidate for the potential treatment of Alpha-1 Antitrypsin Deficiency (AATD). Preclinical studies demonstrated that KRRO-111 achieved over 90% editing of the SERPINA1 transcript in vivo, translating to approximately 90% repaired functional AAT protein in plasma in a mouse model. The therapeutic also nearly eliminated active Z-protein production and progressively cleared pre-existing aggregates, positioning it as a potential best-in-class subcutaneous treatment. The company is well-capitalized with a cash runway into the second half of 2028.
Key Highlights
- Korro Bio added KRRO-111 to its pipeline for Alpha-1 Antitrypsin Deficiency (AATD).
- KRRO-111 achieved >90% editing of SERPINA1 transcript in vivo.
- Demonstrated ~90% repaired functional AAT protein in plasma in a mouse model.
- Nearly eliminated active Z-protein production, reducing it by ~95% in PiZZ mice.
- Showed progressive clearance of pre-existing aggregates, reduced by ~69% at day 28.
- KRRO-111 is a subcutaneously delivered GalNAc-conjugated oligonucleotide.
- Korro Bio has cash, cash equivalents, and marketable securities of $157.1 million as of March 31, 2026.
- Company has cash runway into H2 2028, enabling multiple milestones.
Price Impact
More from KRRO